Protecting newborns from RSV with maternal vaccine and newborn antibody
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
Looks at whether a vaccine given during pregnancy or a long-lasting antibody given to newborns prevents RSV illness in infants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11231714 on NIH RePORTER |
What this research studies
This project will compare infants who get RSV illness with similar infants who do not to see if maternal vaccination or a long-acting monoclonal antibody given at birth lowers the chance of severe RSV. Researchers will use active surveillance at hospitals and clinics to find cases in both inpatient and outpatient settings. They will combine clinical records, demographic information, virus testing, and immune measurements to understand real-world protection. The work focuses on infants under one year and uses data from multiple clinical sites to reflect routine use outside clinical trials.
Who could benefit from this research
Good fit: Ideal candidates are pregnant people and their newborns or infants under 12 months who receive or are eligible for maternal RSV vaccination or a long-acting monoclonal antibody at participating clinics or hospitals.
Not a fit: Older children, adults, and infants not seen at participating sites or not eligible for perinatal immunoprophylaxis are unlikely to get direct benefit from this project.
Why it matters
Potential benefit: If successful, the findings could show how well maternal vaccines and newborn antibodies protect infants from RSV and help guide vaccination and treatment policies.
How similar studies have performed: Randomized trials have shown maternal RSV vaccines and long-acting monoclonal antibodies can prevent RSV in infants, but real-world effectiveness and implementation questions remain.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Oliveira, Carlos Rafael — Yale University
- Study coordinator: Oliveira, Carlos Rafael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.